UY27939A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- UY27939A1 UY27939A1 UY27939A UY27939A UY27939A1 UY 27939 A1 UY27939 A1 UY 27939A1 UY 27939 A UY27939 A UY 27939A UY 27939 A UY27939 A UY 27939A UY 27939 A1 UY27939 A1 UY 27939A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- diseases
- cannabinoids
- receptor
- decrease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La memoria se refiere a nuevos derivados de pirimidina, a composiciones farmacéuticas que contienen estos compuestos, y a su empleo en el tratamiento de enfermedades, en particular el dolor, enfermedades que están provocadas directa o indirectamente por un aumento o disminución de la actividad del receptor de cannabinoides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0219501A GB0219501D0 (en) | 2002-08-21 | 2002-08-21 | Compounds |
GB0309326A GB0309326D0 (en) | 2003-04-24 | 2003-04-24 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27939A1 true UY27939A1 (es) | 2004-03-31 |
Family
ID=31948030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27939A UY27939A1 (es) | 2002-08-21 | 2003-08-14 | Compuestos |
Country Status (35)
Country | Link |
---|---|
US (2) | US7635701B2 (es) |
EP (2) | EP1878725B1 (es) |
JP (1) | JP4583174B2 (es) |
KR (1) | KR20050058367A (es) |
CN (1) | CN100351239C (es) |
AP (1) | AP2005003219A0 (es) |
AR (1) | AR041016A1 (es) |
AT (2) | ATE489369T1 (es) |
AU (1) | AU2003264076B2 (es) |
BR (1) | BR0313676A (es) |
CA (1) | CA2495880C (es) |
CY (1) | CY1107871T1 (es) |
DE (2) | DE60335151D1 (es) |
DK (1) | DK1539712T3 (es) |
EA (2) | EA012703B1 (es) |
EC (1) | ECSP055613A (es) |
ES (1) | ES2295682T3 (es) |
HK (1) | HK1079193A1 (es) |
IL (2) | IL166552A0 (es) |
IS (1) | IS7749A (es) |
MA (1) | MA27428A1 (es) |
MX (1) | MXPA05001960A (es) |
MY (1) | MY137053A (es) |
NO (1) | NO20051451D0 (es) |
NZ (1) | NZ537886A (es) |
OA (1) | OA12910A (es) |
PE (1) | PE20040898A1 (es) |
PL (1) | PL376047A1 (es) |
PT (1) | PT1539712E (es) |
SI (1) | SI1539712T1 (es) |
TW (1) | TW200410946A (es) |
UA (1) | UA83194C2 (es) |
UY (1) | UY27939A1 (es) |
WO (1) | WO2004018433A1 (es) |
ZA (1) | ZA200500913B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
CA2499497A1 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
TW200505902A (en) * | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
WO2005096784A2 (en) | 2004-04-08 | 2005-10-20 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
EP1799656A4 (en) | 2004-08-25 | 2009-09-02 | Targegen Inc | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
GB0517188D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
EP1951684B1 (en) | 2005-11-01 | 2016-07-13 | TargeGen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007070760A2 (en) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
CA2643863A1 (en) * | 2006-04-07 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
WO2008014199A2 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
US8236841B2 (en) | 2006-09-13 | 2012-08-07 | Kyowa Hakko Kirin Co., Ltd. | Fused heterocycle derivative |
US7928123B2 (en) | 2006-09-25 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
EP2076499B1 (en) * | 2006-10-04 | 2010-05-12 | F.Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
US7928103B2 (en) | 2006-10-17 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US9422235B2 (en) | 2006-12-19 | 2016-08-23 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
GB0705803D0 (en) * | 2007-03-28 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
KR20100100858A (ko) * | 2007-11-06 | 2010-09-15 | 에모리 유니버시티 | 안전한 nmda 수용체 길항제의 식별 방법 |
EP2217565B1 (en) | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
CA2730037A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
AU2009296838A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which selectively modulate the CB2 receptor |
TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
TW201031650A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione |
AU2010231694A1 (en) | 2009-03-30 | 2011-10-06 | Astellas Pharma Inc. | Pyrimidine compound |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
WO2010147791A1 (en) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor |
US8383651B2 (en) | 2009-09-22 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
JP5746228B2 (ja) | 2010-03-05 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節するテトラゾール化合物 |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
WO2012014963A1 (ja) * | 2010-07-29 | 2012-02-02 | アステラス製薬株式会社 | 縮環ピリジン化合物 |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
US20150261260A1 (en) * | 2013-03-15 | 2015-09-17 | Royce J. Nicholas | Method of water-proofing electronic components |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
SG11201603063WA (en) * | 2013-10-23 | 2016-05-30 | Academia Sinica | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
MX2018012913A (es) | 2016-04-22 | 2019-01-30 | Receptor Life Sciences Inc | Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion. |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5518A (en) | 1848-04-18 | Geaijst-drieb | ||
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
HUT63941A (en) | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
DK0644755T3 (da) | 1992-06-10 | 1997-09-22 | Nanosystems Llc | Overflademodificerede NSAID-nanopartikler |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
PL185544B1 (pl) | 1995-02-13 | 2003-05-30 | Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny | |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
CA2230894A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
EP0855906B1 (en) | 1995-10-17 | 2008-02-20 | Jagotec AG | Insoluble drug delivery |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
RO121338B1 (ro) | 1996-04-12 | 2007-03-30 | G.D. Searle & Co. | Derivaţi de benzensulfonamidă, procedeu de preparare a acestora, compoziţie farmaceutică şi utilizarea ca inhibitori de cox-2 |
EP0912518B1 (en) | 1996-07-18 | 2003-09-10 | Merck Frosst Canada & Co. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
PL194557B1 (pl) | 1997-09-05 | 2007-06-29 | Glaxo Group Ltd | Pochodna 2,3-diarylopirazolo[1,5-b]pirydazyny, jej wytwarzanie, kompozycja farmaceutyczna zawierająca pochodną i jej zastosowanie |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
EP1089714B1 (en) | 1998-06-19 | 2003-03-05 | Skyepharma Canada Inc. | Processes to generate particles of water-insoluble compounds of up to 2000 nm in size |
WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
CN1263755C (zh) | 1998-11-03 | 2006-07-12 | 葛兰素集团有限公司 | 作为选择性cox-2抑制剂的吡唑并吡啶衍生物 |
US6180136B1 (en) | 1998-11-10 | 2001-01-30 | Idexx Laboratories, Inc. | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
EP1133280A1 (en) | 1998-11-20 | 2001-09-19 | RTP Pharma Inc. | Method of preparing stable suspensions of insoluble microparticles |
US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
ES2216631T3 (es) | 1999-02-27 | 2004-10-16 | Glaxo Group Limited | Pirazolpiridinas. |
GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
EP1525883A1 (en) | 1999-12-08 | 2005-04-27 | Pharmacia Corporation | Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
MXPA03000051A (es) | 2000-06-28 | 2003-08-19 | Smithkline Beecham Plc | Procedimiento de molido en humedo. |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
AU2001293784B2 (en) | 2000-08-31 | 2007-08-30 | F. Hoffmann-La Roche Ag | 7-OXO pyridopyrimidines as inhibitors of a cellular proliferation |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
US7173027B2 (en) | 2001-01-29 | 2007-02-06 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
US20020183335A1 (en) | 2001-02-20 | 2002-12-05 | Piyasena Hewawasam | 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators |
FR2839718B1 (fr) | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
US7217732B2 (en) | 2002-06-19 | 2007-05-15 | Schering Corporation | Cannabinoid receptor agonists |
US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
AU2003260436A1 (en) | 2002-08-21 | 2004-03-11 | Glaxo Group Limited | Pyrimidine compounds |
UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
CA2499497A1 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
GB0222495D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
GB0222493D0 (en) | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
-
2003
- 2003-08-14 UY UY27939A patent/UY27939A1/es not_active Application Discontinuation
- 2003-08-19 MX MXPA05001960A patent/MXPA05001960A/es active IP Right Grant
- 2003-08-19 SI SI200331088T patent/SI1539712T1/sl unknown
- 2003-08-19 DE DE60335151T patent/DE60335151D1/de not_active Expired - Lifetime
- 2003-08-19 BR BR0313676-0A patent/BR0313676A/pt not_active IP Right Cessation
- 2003-08-19 CA CA2495880A patent/CA2495880C/en not_active Expired - Fee Related
- 2003-08-19 EA EA200700934A patent/EA012703B1/ru not_active IP Right Cessation
- 2003-08-19 UA UAA200501583A patent/UA83194C2/ru unknown
- 2003-08-19 EA EA200500392A patent/EA010130B1/ru not_active IP Right Cessation
- 2003-08-19 TW TW092122692A patent/TW200410946A/zh unknown
- 2003-08-19 DK DK03792388T patent/DK1539712T3/da active
- 2003-08-19 EP EP07119063A patent/EP1878725B1/en not_active Expired - Lifetime
- 2003-08-19 AT AT07119063T patent/ATE489369T1/de not_active IP Right Cessation
- 2003-08-19 PT PT03792388T patent/PT1539712E/pt unknown
- 2003-08-19 AP AP2005003219A patent/AP2005003219A0/xx unknown
- 2003-08-19 US US10/524,470 patent/US7635701B2/en not_active Expired - Fee Related
- 2003-08-19 JP JP2004530220A patent/JP4583174B2/ja not_active Expired - Fee Related
- 2003-08-19 ES ES03792388T patent/ES2295682T3/es not_active Expired - Lifetime
- 2003-08-19 AU AU2003264076A patent/AU2003264076B2/en not_active Ceased
- 2003-08-19 AR ARP030102997A patent/AR041016A1/es unknown
- 2003-08-19 PE PE2003000839A patent/PE20040898A1/es not_active Application Discontinuation
- 2003-08-19 EP EP03792388A patent/EP1539712B1/en not_active Expired - Lifetime
- 2003-08-19 NZ NZ537886A patent/NZ537886A/en unknown
- 2003-08-19 MY MYPI20033143A patent/MY137053A/en unknown
- 2003-08-19 DE DE60317348T patent/DE60317348T2/de not_active Expired - Lifetime
- 2003-08-19 OA OA1200500052A patent/OA12910A/en unknown
- 2003-08-19 WO PCT/EP2003/009217 patent/WO2004018433A1/en active IP Right Grant
- 2003-08-19 KR KR1020057002813A patent/KR20050058367A/ko not_active Application Discontinuation
- 2003-08-19 PL PL03376047A patent/PL376047A1/xx not_active Application Discontinuation
- 2003-08-19 CN CNB038241293A patent/CN100351239C/zh not_active Expired - Fee Related
- 2003-08-19 AT AT03792388T patent/ATE377591T1/de active
-
2005
- 2005-01-27 IL IL16655205A patent/IL166552A0/xx unknown
- 2005-02-01 ZA ZA200500913A patent/ZA200500913B/xx unknown
- 2005-02-18 EC EC2005005613A patent/ECSP055613A/es unknown
- 2005-03-07 MA MA28132A patent/MA27428A1/fr unknown
- 2005-03-17 IS IS7749A patent/IS7749A/is unknown
- 2005-03-18 NO NO20051451A patent/NO20051451D0/no not_active Application Discontinuation
- 2005-11-29 HK HK05110876A patent/HK1079193A1/xx not_active IP Right Cessation
-
2007
- 2007-08-27 IL IL185549A patent/IL185549A0/en unknown
-
2008
- 2008-01-31 CY CY20081100115T patent/CY1107871T1/el unknown
-
2009
- 2009-10-21 US US12/582,861 patent/US20100041654A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27939A1 (es) | Compuestos | |
UY28945A1 (es) | Derivados de pirrolopiridina | |
CR8497A (es) | Derivados de azepinoindol como agentes farmaceuticos | |
ECSP045474A (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 | |
PA8623001A1 (es) | Compuestos de quinolina sustituidos | |
GB0222495D0 (en) | Compounds | |
BRPI0511527A (pt) | compostos e composições como moduladores de ppar | |
CR8759A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores quimioquinas | |
UY27878A1 (es) | Derivados de indolinfenilsulfonamida | |
ECSP056138A (es) | Dihidroquinazolinas sustituidas | |
ECSP045407A (es) | Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf | |
CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
PT1543011E (pt) | Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina | |
CR8775A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
UY27714A1 (es) | 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos. | |
ECSP088283A (es) | Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
ECSP045353A (es) | Derivados de benzoxazinona, su preparación y aplicación como medicamentos | |
GT200300294A (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
AR049876A1 (es) | Composiciones farmaceuticas para tratar enfermedades de la piel que comprenden una combinacion de epinastina y uno o mas minerales adicionales o uno o mas farmacos brutos | |
ECSP088527A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
UY27451A1 (es) | 2,5-diamidoindoles sustituidos y su utilización | |
CR9787A (es) | Derivados de imidazopiridina como ligandos del receptor de canabinoides | |
UY29043A1 (es) | Derivados de diarilmetil piperazina, preparaciones de los mismos y usos de los mismos | |
SV2003000743A (es) | Nuevos derivados de pirazolpiridina sustituidos con piridina ref. lea 34888-sv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150505 |